Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
A large number of EGFR mutant non‐small cell lung cancer patients primordially benefit from first‐line treatment with first‐generation EGFR‐tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. However, multiple acquired resistance mechanisms have been described that limit the clinical...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley
2019-02-01
|
| coleção: | Thoracic Cancer |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1111/1759-7714.12927 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|